Please assess the completion status of the following clinical trial:

Trial Title: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic moderate to severe plaque type psoriasis as diagnosed by a qualified physician at least 6 months prior to baseline and with a PASI score \> 10 at baseline.~* Psoriasis patients with pruritus intensity of ≥ 30 on a 100-point VAS, with a recall period of 24h as part of the PGA-CP, both, at screening and at baseline.~Key Exclusion Criteria:~* Underlying conditions other than psoriasis which in the opinion of the investigator currently cause or influence pruritus of the skin (e.g. drug induced pruritus, renal insufficiency, diabetes).~* Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and guttate) at screening or study start.~* Ongoing use of prohibited psoriasis and non-psoriasis treatments. Washout periods have to be adhered to. If the use of any of the prohibited treatments is required, then the subject may not be included into the study.~* Pregnancy, breast feeding or inadequate contraception (if necessary)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): 300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
- Placebo (Type: PLACEBO_COMPARATOR): Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28

Based on this trial design, predict the completion outcome and termination type (if applicable).